Gynuity Health Projects, New York, NY 10010, USA.
Contraception. 2011 Apr;83(4):322-9. doi: 10.1016/j.contraception.2010.08.009.
Medical abortion is one of the most important advances of the last century in the field of reproductive health. However, the introduction and use of the technology varies widely among countries.
The article examines the commercial, political, regulatory, and legislative history of the introduction of mifepristone-misoprostol in France and the United States.
While the introduction of the technology has been deemed a "success" in each country, existing patterns of medical research, abortion service provision and health care financing came to alter the uptake and use of medical abortion in the two countries.
Proof of safety, efficacy and patient acceptability are in themselves not enough to assure successful introduction and widespread use of medical innovations. However, the case studies illustrate that there is more than one way to arrive at expansion of new technologies.
药物流产是上个世纪生殖健康领域最重要的进步之一。然而,这项技术在各国的引进和使用情况存在很大差异。
本文考察了米非司酮-米索前列醇在法国和美国的引进的商业、政治、监管和立法历史。
虽然该技术在这两个国家都被认为是“成功”的,但现有的医学研究、堕胎服务提供和医疗保健融资模式改变了这两个国家对药物流产的接受和使用。
安全性、有效性和患者可接受性的证据本身并不能保证医疗创新的成功引进和广泛应用。然而,这些案例研究表明,新技术的扩展并非只有一种途径。